ClinicalTrials.gg

Fosun Pharma clinical trials

Also known as Henlius.

Part of Shanghai Fosun High Technology (Group) Co., Ltd., which holds 36.00% as of 2025-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 198 studies whose lead sponsor is Fosun Pharma or one of 11 companies grouped under it. 85 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 13, 2026.

Our grouping of 11 registry names, not the registry’s. See them and correct one ↓

Compare Fosun Pharma with Bristol-Myers Squibb and Hoffmann-La Roche →

Pipeline: 47 programs

Each counted once: 39 with a study Fosun Pharma leads registered in the last two years, 8 more from Fosun Pharma's own pipeline.

  • Phase 1
  • Phase 2
  • Phase 3
  • Named by Fosun Pharma only (no registered study yet; not in the 47)

The 5 of 13 with the most live studies.

Program
Anti-PD-L1 Antibody-drug Conjugate HLX43Phase 3 · Fosun Pharma: Phase 2 · 17 live · Carcinoma, Non-Small-Cell Lung · primary completion Nov 2026☆ Track
serplulimabPhase 3 · 12 live · Small Cell Lung Carcinoma☆ Track
pimurutamabPhase 3 · Fosun Pharma: Phase 2 · 8 live · Carcinoma, Non-Small-Cell Lung · primary completion Jul 2027☆ Track
luvometinibPhase 3 · 6 live · Neurofibromatosis 1 · primary completion Apr 2027☆ Track
dulpatatugPhase 3 · Fosun Pharma: Phase 3 · 5 live · Breast Neoplasms · primary completion Jun 2027☆ Track

8 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Fosun Pharma’s own registered studies; “Fosun Pharma says” is its pipeline, which lists phases by indication. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Fosun Pharma’s studies test, most open studies first — 31 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 31; every drug is on its own page, and each page lists its sponsors.

Coming up

37 of Fosun Pharma’s studies under way reach primary completion within a year, 6 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 2N’26
  2. 6D
  3. 3J’27
  4. 2F
  5. 2M
  6. 5A
  7. 2M
  8. 6J
  9. 2J
  10. 2A
  11. 3S
  12. O
  13. 2N

The 12 nearest

Show 7 more

Add all 37 to your calendar (.ics) → With an account.

All 198 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now8543%Recruiting 42 · Not yet recruiting 40 · Enrolling by invitation 3
  • Under way, not recruiting2915%
  • Completed4623%
  • Stopped early147%Withdrawn 9 · Terminated 3 · Suspended 2
  • Status unknown or other2412%

Phase

  • Phase 187
  • Phase 278
  • Phase 338
  • Early Phase 12

Where

  • China146
  • United States28
  • Australia11
  • Poland6
  • Spain5
  • Georgia5

Over the years

  1. 09
  2. 10
  3. 11
  4. 12
  5. 13
  6. 14
  7. 15
  8. 16
  9. 17
  10. 18
  11. 19
  12. 20
  13. 21
  14. 22
  15. 23
  16. 24
  17. 25
  18. 4126

By the year each study started; 1 started before 2009. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Fosun Pharma.

  • Shanghai Henlius Biotech
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    132 studies →
  • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    35 studies →
  • Alma Lasers
    Acquired — became part of Fosun Pharma, May 27, 2013 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies →
  • Alma Lasers Inc.
    Acquired — became part of Fosun Pharma, May 27, 2013 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Fochon Pharmaceuticals, Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Shenzhen Fosun Kairos Biotechnology Co., Ltd.
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Orinove, Inc.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Breas Medical S.A.R.L.
    Acquired — became part of Fosun Pharma, Mar 15, 2017 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Fosun Adgenvax Biopharmaceutical Co.,Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Breas Medical, Inc.
    Acquired — became part of Fosun Pharma, Mar 15, 2017 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions Fosun Pharma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 198. Browse all 198 →